Silo Pharma Completes 1-for-15 Reverse Stock Split, Adjusts Authorized Shares
Summary
Silo Pharma has completed its 1-for-15 reverse stock split, effective June 2, 2026, with shares now trading on a split-adjusted basis and authorized shares proportionately reduced.
Key Events · Corporate Governance and Compliance · SILO
-
Reverse Stock Split Effective
The 1-for-15 reverse stock split became effective at 4:01 p.m. ET on Tuesday, June 2, 2026, following the filing of a Certificate of Change with the Nevada Secretary of State.
-
Split-Adjusted Trading Commences
The company's common stock began trading on a split-adjusted basis on The Nasdaq Stock Market LLC when it opened on June 3, 2026.
-
Authorized Shares Adjusted
The total authorized common stock was proportionately reduced from 100,000,000 to 6,666,667 shares, with no change to the par value.
-
Fractional Shares Rounded Up
Stockholders who would have been entitled to receive fractional shares had their holdings rounded up to the next whole share.
Analysis · SILO · Life Sciences
This filing confirms the formal execution of the previously announced 1-for-15 reverse stock split. The split became effective on June 2, 2026, with trading on a split-adjusted basis commencing today. This action is typically undertaken by micro-cap companies to increase their per-share price, often to meet minimum listing requirements for exchanges like Nasdaq and to make the stock more attractive to institutional investors. The reduction in authorized shares also impacts the company's future capital raising capacity.
At the time of this filing, SILO was trading at $6.29 on NASDAQ in the Life Sciences sector. The 52-week trading range was $0.22 to $6.26. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.